Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF<sup>V600E</sup> Protein
BRAF is a serine/threonine kinase frequently mutated in human cancers. BRAF<sup>V600E</sup> mutated protein is targeted through the use of kinase inhibitors which are approved for the treatment of melanoma; however, their long-term efficacy is hampered by resistance mechanisms. The PROTA...
Main Authors: | Elisabetta Marini, Marco Marino, Giulia Gionfriddo, Federica Maione, Marta Pandini, Daniele Oddo, Marta Giorgis, Barbara Rolando, Federica Blua, Simone Gastaldi, Serena Marchiò, Sandra Kovachka, Francesca Spyrakis, Eleonora Gianquinto, Federica Di Nicolantonio, Massimo Bertinaria |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-12-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/27/23/8513 |
Similar Items
-
Eruptive nevi in the setting of encorafenib: A case report and literature review
by: Marisa Lenga, BS, et al.
Published: (2025-02-01) -
Estrogen Receptor-α Targeting: PROTACs, SNIPERs, Peptide-PROTACs, Antibody Conjugated PROTACs and SNIPERs
by: Arvind Negi, et al.
Published: (2022-11-01) -
BAYONET trial: staged combination with encorafenib, binimetinib, plus cetuximab following encorafenib plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer
by: Y. Matsubara, et al.
Published: (2024-06-01) -
PROTAC<sup>®</sup> technology and potential for its application in infection control
by: M. A. Zakharova, et al.
Published: (2024-07-01) -
Sweet syndrome in a patient receiving encorafenib and binimetinib therapy for malignant melanoma
by: Myiah Quach, BS, et al.
Published: (2024-03-01)